{
    "q": [
        {
            "docid": "7800672_21",
            "document": "History of animal testing . The non-human primate models of AIDS, using HIV-2, SHIV, and SIV in macaques, have been used as a complement to ongoing research efforts against the virus. The drug tenofovir has had its efficacy and toxicology evaluated in macaques and found long-term/high-dose treatments had adverse effects not found using short-term/high-dose treatment followed by long-term/low-dose treatment. This finding in macaques was translated into human dosing regimens. Prophylactic treatment with anti-virals has been evaluated in macaques because an introduction of the virus can only be controlled in an animal model. The finding that prophylaxis can be effective at blocking infection has altered the treatment for occupational exposures, such as needle exposures. Such exposures are now followed rapidly with anti-HIV drugs, and this practice has resulted in measurable transient virus infection similar to the NHP model. Similarly, the mother-to-fetus transmission, and its fetal prophylaxis with antivirals such as tenofovir and AZT, has been evaluated in controlled testing in macaques not possible in humans, and this knowledge has guided antiviral treatment in pregnant mothers with HIV. \"The comparison and correlation of results obtained in monkey and human studies are leading to a growing validation and recognition of the relevance of the animal model. Although each animal model has its limitations, carefully designed drug studies in nonhuman primates can continue to advance our scientific knowledge and guide future clinical trials.\"",
            "score": 131.6833953857422
        },
        {
            "docid": "8010519_40",
            "document": "Animal testing on non-human primates . The non-human primate models of AIDS, using HIV-2, SHIV, and SIV in macaques, have been used as a complement to ongoing research efforts against the virus. The drug tenofovir has had its efficacy and toxicology evaluated in macaques, and found longterm-highdose treatments had adverse effects not found using short term-high dose treatment followed by long term-low dose treatment. This finding in macaques was translated into human dosing regimens. Prophylactic treatment with anti-virals has been evaluated in macaques, because introduction of the virus can only be controlled in an animal model. The finding that prophylaxis can be effective at blocking infection has altered the treatment for occupational exposures, such as needle exposures. Such exposures are now followed rapidly with anti-HIV drugs, and this practice has resulted in measurable transient virus infection similar to the NHP model. Similarly, the mother-to-fetus transmission, and its fetal prophylaxis with antivirals such as tenofovir and AZT, has been evaluated in controlled testing in macaques not possible in humans, and this knowledge has guided antiviral treatment in pregnant mothers with HIV. \"The comparison and correlation of results obtained in monkey and human studies is leading to a growing validation and recognition of the relevance of the animal model. Although each animal model has its limitations, carefully designed drug studies in nonhuman primates can continue to advance our scientific knowledge and guide future clinical trials.\"",
            "score": 128.7383050918579
        },
        {
            "docid": "10449471_17",
            "document": "Dose (biochemistry) . The infectious dose of a pathogen is the number of cells required to infect the host. All pathogens have an infectious dose typically given in number of cells. The infectious dose varies by organism and can be dependent on the specific type of strain. Some pathogens can infect a host with only a few cells, while others require millions or billions.",
            "score": 109.55336904525757
        },
        {
            "docid": "10449471_18",
            "document": "Dose (biochemistry) . Examples of infectious doses, ranked loosely in increasing order:  Typically, stomach acids can kill bacteria below the infectious dosing rage for a given pathogen and keep the host from feeling symptoms or falling ill. Complexes constructed by fat can protect infectious agents from stomach acid, making fatty foods more likely to contain pathogens that successfully infect the host. For individuals with low or reduced stomach acid concentrations, in infectious dosage for a pathogen will be lower than normal.",
            "score": 89.96417617797852
        },
        {
            "docid": "26069912_5",
            "document": "Virus quantification . 50% Tissue culture Infective Dose (TCID) is the measure of infectious virus titer. This endpoint dilution assay quantifies the amount of virus required to kill 50% of infected hosts or to produce a cytopathic effect in 50% of inoculated tissue culture cells. This assay may be more common in clinical research applications where the lethal dose of virus must be determined or if the virus does not form plaques. When used in the context of tissue culture, host cells are plated and serial dilutions of the virus are added. After incubation, the percentage of cell death (i.e. infected cells) is manually observed and recorded for each virus dilution, and results are used to mathematically calculate a TCID result. Due to distinct differences in assay methods and principles, TCID and pfu/mL or other infectivity assay results are not equivalent. This method can take up to a week due to cell infectivity time.",
            "score": 82.36997151374817
        },
        {
            "docid": "26174425_2",
            "document": "Infectious dose . Infectious dose (ID) is the amount of pathogen (measured in number of microorganisms) required to cause an infection in the host.",
            "score": 90.45499849319458
        },
        {
            "docid": "357756_16",
            "document": "Poliovirus . The primary determinant of infection for any virus is its ability to enter a cell and produce additional infectious particles. The presence of CD155 is thought to define the animals and tissues that can be infected by poliovirus. CD155 is found (outside of laboratories) only on the cells of humans, higher primates, and Old World monkeys. Poliovirus is, however, strictly a human pathogen, and does not naturally infect any other species (although chimpanzees and Old World monkeys can be experimentally infected).",
            "score": 72.86856365203857
        },
        {
            "docid": "10449471_2",
            "document": "Dose (biochemistry) . A dose is a measured quantity of a medicine, nutrient, or pathogen which is delivered as a unit. The greater the quantity delivered, the larger the dose. Doses are most commonly measured for compounds in medicine. The term is usually applied to the quantity of a drug or other agent administered for therapeutic purposes, but may be used to describe any case where a substance is introduced to the body. In nutrition, the term is usually applied to how much of a specific nutrient is in a person's diet or in a particular food, meal, or dietary supplement. For bacterial or viral agents, dose typically refers to the amount of the pathogen required to infect a host. For information on dosage of toxic substances, see Toxicology. For information on excessive intake of pharmaceutical agents, see Drug overdose.",
            "score": 89.31763696670532
        },
        {
            "docid": "1171686_12",
            "document": "Regulatory T cell . An important question in the field of immunology is how the immunosuppressive activity of regulatory T cells is modulated during the course of an ongoing immune response. While the immunosuppressive function of regulatory T cells prevents the development of autoimmune disease, it is not desirable during immune responses to infectious microorganisms. Current hypotheses suggest that, upon encounter with infectious microorganisms, the activity of regulatory T cells may be downregulated, either directly or indirectly, by other cells to facilitate elimination of the infection. Experimental evidence from mouse models suggests that some pathogens may have evolved to manipulate regulatory T cells to immunosuppress the host and so potentiate their own survival. For example, regulatory T cell activity has been reported to increase in several infectious contexts, such as retroviral infections (the most well-known of which is HIV), mycobacterial infections (like tuberculosis), and various parasitic infections including \"Leishmania\" and malaria.",
            "score": 63.456663846969604
        },
        {
            "docid": "39761773_6",
            "document": "Central nervous system effects from radiation exposure during spaceflight . Research with animal models that are irradiated with HZE nuclei has shown that important changes to the CNS occur with the dose levels that are of concern to NASA. However, the significance of these results on the morbidity to astronauts has not been elucidated. One model of late tissue effects suggests that significant effects will occur at lower doses, but with increased latency. It is to be noted that the studies that have been conducted to date have been carried out with relatively small numbers of animals (<10 per dose group); therefore, testing of dose threshold effects at lower doses (< 0.5 Gy) has not been carried out sufficiently at this time. As the problem of extrapolating space radiation effects in animals to humans will be a challenge for space radiation research, such research could become limited by the population size that is used in animal studies. Furthermore, the role of dose protraction has not been studied to date. An approach to extrapolate existing observations to possible cognitive changes, performance degradation, or late CNS effects in astronauts has not been discovered. New approaches in systems biology offer an exciting tool to tackle this challenge. Recently, eight gaps were identified for projecting CNS risks. Research on new approaches to risk assessment may be needed to provide the necessary data and knowledge to develop risk projection models of the CNS from space radiation.",
            "score": 102.76732456684113
        },
        {
            "docid": "7038_23",
            "document": "Candidiasis . Vaginal yeast infections are typically treated with topical antifungal agents. A one-time dose of fluconazole is 90% effective in treating a vaginal yeast infection. For severe nonrecurring cases, several doses of fluconazole is recommended. Local treatment may include vaginal suppositories or medicated douches. Other types of yeast infections require different dosing. Gentian violet can be used for thrush in breastfeeding babies. \"C. albicans\" can develop resistance to fluconazole, this being more of an issue in those with HIV/AIDS who are often treated with multiple courses of fluconazole for recurrent oral infections.",
            "score": 87.3937623500824
        },
        {
            "docid": "30942180_5",
            "document": "Cancer slope factor . When the chemical is a known or probable human carcinogen, a toxicity value that defines quantitatively the relationship between dose and response (i.e., the slope factor) is calculated. Because risk at low exposure levels is difficult to measure directly either by animal experiments or by epidemiologic studies, the development of a slope factor generally entails applying a model to the available \"data set\" and using the model to extrapolate from the relatively high doses administered to experimental animals (or the exposures noted in epidemiologic studies) to the lower exposure levels expected for human contact in the environment.",
            "score": 86.36727905273438
        },
        {
            "docid": "37220_7",
            "document": "Infection . One way of proving that a given disease is \"infectious\", is to satisfy Koch's postulates (first proposed by Robert Koch), which demands that the infectious agent be identified only in patients and not in healthy controls, and that patients who contract the agent also develop the disease. These postulates were first used in the discovery that Mycobacteria species cause tuberculosis. Koch's postulates cannot be applied ethically for many human diseases because they require experimental infection of a healthy individual with a pathogen produced as a pure culture. Often, even clearly infectious diseases do not meet the infectious criteria. For example, \"Treponema pallidum\", the causative spirochete of syphilis, cannot be cultured \"in vitro\" \u2013 however the organism can be cultured in rabbit testes. It is less clear that a pure culture comes from an animal source serving as host than it is when derived from microbes derived from plate culture. Epidemiology is another important tool used to study disease in a population. For infectious diseases it helps to determine if a disease outbreak is sporadic (occasional occurrence), endemic (regular cases often occurring in a region), epidemic (an unusually high number of cases in a region), or pandemic (a global epidemic).",
            "score": 99.76750922203064
        },
        {
            "docid": "35993194_35",
            "document": "Radiation-induced cancer . In all three cases, the values of alpha and beta must be determined by regression from human exposure data. Laboratory experiments on animals and tissue samples is of limited value. Most of the high quality human data available is from high dose individuals, above 0.1 Sv, so any use of the models at low doses is an extrapolation that might be under-conservative or over-conservative. There is not enough human data available to settle decisively which of these model might be most accurate at low doses. The consensus has been to assume linear no-threshold because it the simplest and most conservative of the three.",
            "score": 82.85738611221313
        },
        {
            "docid": "147020_19",
            "document": "Hygiene . Good home hygiene means engaging in hygiene practices at critical points to break the chain of infection. Because the \"infectious dose\" for some pathogens can be very small (10-100 viable units or even less for some viruses), and infection can result from direct transfer of pathogens from surfaces via hands or food to the mouth, nasal mucosa or the eye, 'hygienic cleaning' procedures should be sufficient to eliminate pathogens from critical surfaces.",
            "score": 77.29946231842041
        },
        {
            "docid": "34405048_7",
            "document": "Kauri dieback . A number of compounds have been identified which are active \"in vitro\" against the causative pathogen responsible for Kauri dieback, including common broad-spectrum antifungal agents such as copper sulphate. However, there is as yet no established treatment for infected trees, with the large size of mature Kauri trees and the remote location of many infected areas making any treatment challenging. Trials are underway using injections of phosphite into infected Kauri trees, as this is an established treatment against other species of \"Phytophthora\" in fruit trees such as avocados. However while this has proved effective in younger trees, it has proved challenging to calculate the correct dose and administer it successfully to large mature Kauri trees without causing unacceptable toxicity. Another concern with phosphite treatment is that it can suppress symptoms of infection but without actually eliminating the \"Phytophthora\" pathogen, potentially allowing it to continue to spread to healthy trees nearby, or reappear if phosphite treatments are interrupted.",
            "score": 68.16568732261658
        },
        {
            "docid": "1025510_6",
            "document": "Coxiella burnetii . The ID (the dose needed to infect 50% of experimental subjects) is one via inhalation; i.e., inhalation of one organism will yield disease in 50% of the population. This is an extremely low infectious dose (only 1-10 organisms required), making \"C. burnetii\" one of the most infectious known organisms. Disease occurs in two stages: an acute stage that presents with headaches, chills, and respiratory symptoms, and an insidious chronic stage.",
            "score": 72.99581336975098
        },
        {
            "docid": "4191_2",
            "document": "BCG vaccine . Bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). In countries where tuberculosis or leprosy is common, one dose is recommended in healthy babies as close to the time of birth as possible. In areas where tuberculosis is not common, only children at high risk are typically immunized, while suspected cases of tuberculosis are individually tested for and treated. Adults who do not have tuberculosis and have not been previously immunized but are frequently exposed may be immunized as well. BCG also has some effectiveness against Buruli ulcer infection and other nontuberculous mycobacteria infections. Additionally it is also often used as part of the treatment of bladder cancer. Rates of protection against tuberculosis infection vary widely and protection lasts up to twenty years. Among children it prevents about 20% from getting infected and among those who do get infected it protects half from developing disease. The vaccine is given by injection into the skin. Additional doses are not supported by evidence. It may also be used in the treatment of some types of bladder cancers. Serious side effects are rare. Often there is redness, swelling, and mild pain at the site of injection. A small ulcer may also form with some scarring after healing. Side effects are more common and potentially more severe in those with poor immune function. It is not safe for use during pregnancy. The vaccine was originally developed from \"Mycobacterium bovis\" which is commonly found in cows. While it has been weakened, it is still live. The BCG vaccine was first used medically in 1921. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Between 2011 and 2014 the wholesale price was $0.16 to $1.11 USD a dose in the developing world. In the United States it costs $100 to $200 USD. As of 2004 the vaccine is given to about 100 million children per year globally.",
            "score": 95.76774084568024
        },
        {
            "docid": "7325282_15",
            "document": "HIV/AIDS in Pakistan . Lack of the ability to measure the outcomes or impact of interventions in real time (so that this knowledge can inform program direction) was likely the most important factor in the low performance of the first Enhanced Program. Other challenges that must be overcome include establishment of a transparent financial management and a smooth logistical and procurement system. Much of the Enhanced Program services are contracted out and delays in procurement of these services meant that many of the cities went without services for months to years. More complex (and longer term) challenges will include determining how to integrate many of HIV activities within other health activities, improve planning to anticipate future direction of the epidemic and its response and to enhance efficiency and effectiveness of the interventions. For these research must become part of the interventions to guide their implementation using local context and to involve epidemiological tools such as routine analysis of available data and even mathematical modeling to guide program planning. After devolution in 2011 the Provinces mobilized their own resources that were mainly used to prevent the infection from establishing in Key Populations. The country also succeeded in getting three Global Fund grants and the present grant is more directed to strengthening HIV treatment care and support services to HIV positives and their families . However, the available information suggests a slower case detection and confirmation and any response services for the infected population. This may be resulting from the fact that HIV is mainly confined to high risk population mentioned above. However, it can not be ruled out mainly due to the strong stigma attached, main surveys focused only in the urban areas and general population not having access to free laboratory test.",
            "score": 68.44267284870148
        },
        {
            "docid": "443854_21",
            "document": "Rh disease . Animal studies had previously been conducted by William Pollack, using a rabbit model of Rh. This model, named the rabbit HgA-F system, was a perfect animal model of human Rh, and enabled Pollack's team to gain experience in preventing hemolytic disease in rabbits by giving specific HgA antibody, as was later done with Rh-negative mothers. One of the needs was a dosing experiment that could be used to determine the level of circulating Rh-positive cells in an Rh-negative pregnant female derived from her Rh-positive fetus. This was first done in the rabbit system, but subsequent human tests at the University of Manitoba conducted under Pollack's direction confirmed that this result matched the human dosing perfectly. The dose is 20 \u00b5G of antibody for 1mL of Rh-positive red cells.",
            "score": 104.9036192893982
        },
        {
            "docid": "39761773_41",
            "document": "Central nervous system effects from radiation exposure during spaceflight . Reliable projections for CNS risks from space radiation exposure cannot be made at this time due to a paucity of data on the subject. Existing animal and cellular data do suggest that space radiation can produce neurological and behavioral effects; therefore, it is possible that mission operations will be impacted. The significance of these results on the morbidity to astronauts has not been elucidated, however. It is to be noted that studies, to date, have been carried out with relatively small numbers of animals (<10 per dose group); this means that testing of dose threshold effects at lower doses (<0.5 Gy) has not yet been carried out to a sufficient extent. As the problem of extrapolating space radiation effects in animals to humans will be a challenge for space radiation research, such research could become limited by the population size that is typically used in animal studies. Furthermore, the role of dose protraction has not been studied to date. An approach has not been discovered to extrapolate existing observations to possible cognitive changes, performance degradation, or late CNS effects in astronauts. Research on new approaches to risk assessment may be needed to provide the data and knowledge that will be necessary to develop risk projection models of the CNS from space radiation. A vigorous research program, which will be required to solve these problems, must rely on new approaches to risk assessment and countermeasure validation because of the absence of useful human radio-epidemiology data in this area.",
            "score": 98.46201992034912
        },
        {
            "docid": "1449983_3",
            "document": "Natural reservoir . Because of the enormous variety of infectious microorganisms capable of causing disease, precise definitions for what constitutes a natural reservoir are numerous, various, and often conflicting. The reservoir concept applies only for pathogens capable of infecting more than one host population and only with respect to a defined target population \u2013 the population of organisms in which the pathogen causes disease. The reservoir is any population of organisms (or any environment) which harbors the pathogen and transmits it to the target population. Reservoirs may comprise one or more different species, may be the same or a different species as the target, and, in the broadest sense, may include vector species, which are otherwise distinct from natural reservoirs and should not be confused with them. Significantly, species considered reservoirs for a given pathogen may not experience symptoms of disease when infected by the pathogen.",
            "score": 68.56230807304382
        },
        {
            "docid": "20423_77",
            "document": "Malaria . Nearly 200 parasitic \"Plasmodium\" species have been identified that infect birds, reptiles, and other mammals, and about 30 species naturally infect non-human primates. Some malaria parasites that affect non-human primates (NHP) serve as model organisms for human malarial parasites, such as \"P.\u00a0coatneyi\" (a model for \"P.\u00a0falciparum\") and \"P.\u00a0cynomolgi\" (\"P.\u00a0vivax\"). Diagnostic techniques used to detect parasites in NHP are similar to those employed for humans. Malaria parasites that infect rodents are widely used as models in research, such as \"P.\u00a0berghei\". Avian malaria primarily affects species of the order Passeriformes, and poses a substantial threat to birds of Hawaii, the Galapagos, and other archipelagoes. The parasite \"P.\u00a0relictum\" is known to play a role in limiting the distribution and abundance of endemic Hawaiian birds. Global warming is expected to increase the prevalence and global distribution of avian malaria, as elevated temperatures provide optimal conditions for parasite reproduction.",
            "score": 52.743348598480225
        },
        {
            "docid": "18644_10",
            "document": "Median lethal dose . For disease-causing organisms, there is also a measure known as the median infective dose and dosage. The median infective dose (ID) is the number of organisms received by a person or test animal qualified by the route of administration (e.g., 1,200 org/man per oral). Because of the difficulties in counting actual organisms in a dose, infective doses may be expressed in terms of biological assay, such as the number of LD's to some test animal. In biological warfare infective dosage is the number of infective doses per cubic metre of air times the number of minutes of exposure (e.g., ICt is 100 medium doses - min/m).",
            "score": 111.45236659049988
        },
        {
            "docid": "58911_16",
            "document": "Measles . In developing countries where measles is common, the World Health Organization recommend two doses of vaccine be given at six and nine months of age. The vaccine should be given whether the child is HIV-infected or not. The vaccine is less effective in HIV-infected infants than in the general population, but early treatment with antiretroviral drugs can increase its effectiveness. Measles vaccination programs are often used to deliver other child health interventions, as well, such as bed nets to protect against malaria, antiparasite medicine and vitamin A supplements, and so contribute to the reduction of child deaths from other causes.",
            "score": 84.23862075805664
        },
        {
            "docid": "170927_2",
            "document": "Whooping cough . Whooping cough (also known as pertussis or 100-day cough) is a highly contagious bacterial disease. Initially, symptoms are usually similar to those of the common cold with a runny nose, fever, and mild cough. This is then followed by weeks of severe coughing fits. Following a fit of coughing, a high-pitched whoop sound or gasp may occur as the person breathes in. The coughing may last for 10 or more weeks, hence the phrase \"100-day cough\". A person may cough so hard that they vomit, break ribs, or become very tired from the effort. Children less than one year old may have little or no cough and instead have periods where they do not breathe. The time between infection and the onset of symptoms is usually seven to ten days. Disease may occur in those who have been vaccinated, but symptoms are typically milder. Pertussis is caused by the bacterium \"Bordetella pertussis\". It is an airborne disease which spreads easily through the coughs and sneezes of an infected person. People are infectious to others from the start of symptoms until about three weeks into the coughing fits. Those treated with antibiotics are no longer infectious after five days. Diagnosis is by collecting a sample from the back of the nose and throat. This sample can then be tested by either culture or by polymerase chain reaction. Prevention is mainly by vaccination with the pertussis vaccine. Initial immunization is recommended between six and eight weeks of age, with four doses to be given in the first two years of life. The vaccine becomes less effective over time, with additional doses often recommended for older children and adults. Antibiotics may be used to prevent the disease in those who have been exposed and are at risk of severe disease. In those with the disease, antibiotics are useful if started within three weeks of the initial symptoms, but otherwise have little effect in most people. In children less than one year old and among those who are pregnant, they are recommended within six weeks of symptom onset. Antibiotics used include erythromycin, azithromycin, clarithromycin, or trimethoprim/sulfamethoxazole. Evidence to support interventions, other than antibiotics, for the cough is poor. Many children less than a year of age require hospitalization. An estimated 16.3\u00a0million people worldwide were infected in 2015. Most cases occur in the developing world, and people of all ages may be affected. In 2015, it resulted in 58,700 deaths \u2013 down from 138,000 deaths in 1990. Nearly 0.5% of infected children less than one year of age die. Outbreaks of the disease were first described in the 16th century. The bacterium that causes the infection was discovered in 1906. The pertussis vaccine became available in the 1940s.",
            "score": 91.85945010185242
        },
        {
            "docid": "50415503_7",
            "document": "Pterygodermatites peromysci . In a field study to determine if there was sex-biased infection towards male mice, female and male mice were separated into groups and administered an antihelminthic drug to clear the infection of \"P. peromysci\" adults in infected rodents to test if males or females released more infectious eggs ingested by cricket intermediate hosts. The antihelminthic drug was levamisole hydrochloride which when tested in the infected mice was shown to be able to control and prevent infection of \"P. peromysci\" in both the male and female mice for up to 2 weeks optimally, but no longer than 4 weeks for the dose given (7). Probably after 2 weeks of the treatment dose (36\u00a0mg / kg) the free mice were susceptible to reinfection.",
            "score": 75.56315684318542
        },
        {
            "docid": "5009_42",
            "document": "Zebrafish . As the immune system is relatively conserved between zebrafish and humans, many human infectious diseases can be modeled in zebrafish. The transparent early life stages are well suited for \"in vivo\" imaging and genetic dissection of host-pathogen interactions. Zebrafish models for a wide range of bacterial, viral and parasitic pathogens have already been established; for example, the zebrafish model for tuberculosis provides fundamental insights into the mechanisms of pathogenesis of mycobacteria. Furthermore, robotic technology has been developed for high-throughput antimicrobial drug screening using zebrafish infection models.",
            "score": 66.23437833786011
        },
        {
            "docid": "1449983_5",
            "document": "Natural reservoir . The great diversity of infectious pathogens, their possible hosts, and the ways in which their hosts respond to infection has resulted in multiple definitions for \"natural reservoir\", many of which are conflicting or incomplete. In a 2002 conceptual exploration published in the CDC's \"Emerging Infectious Diseases\", the natural reservoir of a given pathogen is defined as \"one or more epidemiologically connected populations or environments in which the pathogen can be permanently maintained and from which infection is transmitted to the defined target population.\" The \"target population\" is the population or species in which the pathogen causes disease; it is the population of interest because it suffers from disease when infected by the pathogen (for example, humans are the target population in most medical epidemiological studies).",
            "score": 61.44624447822571
        },
        {
            "docid": "33894099_28",
            "document": "Ticks of domestic animals . Vaccination against \"An. marginale\" is done using live strains of the cross-reactive \"An. centrale\". Vaccines are available on a commercial basis to immunize cattle against \"Babesia bovis\". This is made by serial infection of calves to attenuate the virulence of the strain of \"Babesia\", followed by splenectomy to produce many of the piroplasm stage in blood, which is then bottled for use. The vaccine is delivered containing the live protozoa to induce immunity without acute disease. \"Theileria annulata\" can be grown and attenuated in virulence by means of infecting cell cultures with the schizont stage of the protozoan. This is delivered as a frozen vaccine from which live parasites are thawed out before injection. Cattle can be protected against East Coast fever by an infection-and-treatment procedure. \"Rhipicephalus appendiculatus\" ticks are infected with \"Theileria parva\" under laboratory conditions; theilerial sporozoites are extracted from the ticks and stored in liquid nitrogen; infective doses of the live vaccine are delivered to identified cattle and a few days later a protective dose of antibiotic is delivered to stop the infection from developing into clinical East Coast fever. Vaccines are often highly effective, but the live parasite vaccines have problems of potential contamination with other microbes and induction of a carrier state which may be unwanted. Intensive attempts are made to develop vaccines to control these diseases using recombinant DNA techniques to synthesize the relevant antigens, but as with vaccines against human malaria this is a difficult technological challenge.",
            "score": 98.55064141750336
        },
        {
            "docid": "20423_70",
            "document": "Malaria . Immunity (or, more accurately, tolerance) to \"P.\u00a0falciparum\" malaria does occur naturally, but only in response to years of repeated infection. An individual can be protected from a \"P.\u00a0falciparum\" infection if they receive about a thousand bites from mosquitoes that carry a version of the parasite rendered non-infective by a dose of X-ray irradiation. The highly polymorphic nature of many \"P.\u00a0falciparum\" proteins results in significant challenges to vaccine design. Vaccine candidates that target antigens on gametes, zygotes, or ookinetes in the mosquito midgut aim to block the transmission of malaria. These transmission-blocking vaccines induce antibodies in the human blood; when a mosquito takes a blood meal from a protected individual, these antibodies prevent the parasite from completing its development in the mosquito. Other vaccine candidates, targeting the blood-stage of the parasite's life cycle, have been inadequate on their own. For example, SPf66 was tested extensively in areas where the disease is common in the 1990s, but trials showed it to be insufficiently effective.",
            "score": 66.87164664268494
        },
        {
            "docid": "575776_10",
            "document": "Lethal dose . The median infective dose (ID) is the number of organisms received by a person or test animal qualified by the route of administration (e.g., 1,200 org/man per oral). Because of the difficulties in counting actual organisms in a dose, infective doses may be expressed in terms of biological assay, such as the number of LD's to some test animal. In biological warfare infective dosage is the number of infective doses per minute for a cubic meter (e.g., ICt is 100 medium doses - min/m).)",
            "score": 106.56378483772278
        }
    ],
    "r": [
        {
            "docid": "7800672_21",
            "document": "History of animal testing . The non-human primate models of AIDS, using HIV-2, SHIV, and SIV in macaques, have been used as a complement to ongoing research efforts against the virus. The drug tenofovir has had its efficacy and toxicology evaluated in macaques and found long-term/high-dose treatments had adverse effects not found using short-term/high-dose treatment followed by long-term/low-dose treatment. This finding in macaques was translated into human dosing regimens. Prophylactic treatment with anti-virals has been evaluated in macaques because an introduction of the virus can only be controlled in an animal model. The finding that prophylaxis can be effective at blocking infection has altered the treatment for occupational exposures, such as needle exposures. Such exposures are now followed rapidly with anti-HIV drugs, and this practice has resulted in measurable transient virus infection similar to the NHP model. Similarly, the mother-to-fetus transmission, and its fetal prophylaxis with antivirals such as tenofovir and AZT, has been evaluated in controlled testing in macaques not possible in humans, and this knowledge has guided antiviral treatment in pregnant mothers with HIV. \"The comparison and correlation of results obtained in monkey and human studies are leading to a growing validation and recognition of the relevance of the animal model. Although each animal model has its limitations, carefully designed drug studies in nonhuman primates can continue to advance our scientific knowledge and guide future clinical trials.\"",
            "score": 131.6833953857422
        },
        {
            "docid": "8010519_40",
            "document": "Animal testing on non-human primates . The non-human primate models of AIDS, using HIV-2, SHIV, and SIV in macaques, have been used as a complement to ongoing research efforts against the virus. The drug tenofovir has had its efficacy and toxicology evaluated in macaques, and found longterm-highdose treatments had adverse effects not found using short term-high dose treatment followed by long term-low dose treatment. This finding in macaques was translated into human dosing regimens. Prophylactic treatment with anti-virals has been evaluated in macaques, because introduction of the virus can only be controlled in an animal model. The finding that prophylaxis can be effective at blocking infection has altered the treatment for occupational exposures, such as needle exposures. Such exposures are now followed rapidly with anti-HIV drugs, and this practice has resulted in measurable transient virus infection similar to the NHP model. Similarly, the mother-to-fetus transmission, and its fetal prophylaxis with antivirals such as tenofovir and AZT, has been evaluated in controlled testing in macaques not possible in humans, and this knowledge has guided antiviral treatment in pregnant mothers with HIV. \"The comparison and correlation of results obtained in monkey and human studies is leading to a growing validation and recognition of the relevance of the animal model. Although each animal model has its limitations, carefully designed drug studies in nonhuman primates can continue to advance our scientific knowledge and guide future clinical trials.\"",
            "score": 128.73831176757812
        },
        {
            "docid": "18644_10",
            "document": "Median lethal dose . For disease-causing organisms, there is also a measure known as the median infective dose and dosage. The median infective dose (ID) is the number of organisms received by a person or test animal qualified by the route of administration (e.g., 1,200 org/man per oral). Because of the difficulties in counting actual organisms in a dose, infective doses may be expressed in terms of biological assay, such as the number of LD's to some test animal. In biological warfare infective dosage is the number of infective doses per cubic metre of air times the number of minutes of exposure (e.g., ICt is 100 medium doses - min/m).",
            "score": 111.45236206054688
        },
        {
            "docid": "175596_52",
            "document": "Animal testing . These toxicity tests provide, in the words of a 2006 United States National Academy of Sciences report, \"critical information for assessing hazard and risk potential\". Animal tests may overestimate risk, with false positive results being a particular problem, but false positives appear not to be prohibitively common. Variability in results arises from using the effects of high doses of chemicals in small numbers of laboratory animals to try to predict the effects of low doses in large numbers of humans. Although relationships do exist, opinion is divided on how to use data on one species to predict the exact level of risk in another.",
            "score": 110.5268325805664
        },
        {
            "docid": "10449471_17",
            "document": "Dose (biochemistry) . The infectious dose of a pathogen is the number of cells required to infect the host. All pathogens have an infectious dose typically given in number of cells. The infectious dose varies by organism and can be dependent on the specific type of strain. Some pathogens can infect a host with only a few cells, while others require millions or billions.",
            "score": 109.5533676147461
        },
        {
            "docid": "575776_10",
            "document": "Lethal dose . The median infective dose (ID) is the number of organisms received by a person or test animal qualified by the route of administration (e.g., 1,200 org/man per oral). Because of the difficulties in counting actual organisms in a dose, infective doses may be expressed in terms of biological assay, such as the number of LD's to some test animal. In biological warfare infective dosage is the number of infective doses per minute for a cubic meter (e.g., ICt is 100 medium doses - min/m).)",
            "score": 106.56378173828125
        },
        {
            "docid": "29445941_5",
            "document": "Animals and tobacco smoke . The second method, as described by the IARC monographs, used to measure the carcinogenicity of cigarette smoke to animals is by exposing them to mainstream cigarette smoke. The IARC monographs define mainstream cigarette smoke as that which is emitted by the mouth end of the cigarette and therefore the smoke that human smokers would be exposed to most. The IARC monographs describe the methods and equipment that scientists have developed to make more effective and standardize the deliverance of mainstream cigarette smoke. These devices vary between whole-body and nose-only exposure, but typically involve machine smoked cigarette smoke being pumped into a small chamber that contains the animal test subjects. A variety of factors differentiate the experience of a human smoker from these animal test subjects'. Human smokers inhale smoke voluntarily and therefore do so more deeply than do animal test subjects which typically adopt short, shallow breaths when exposed to smoke. The animal test subjects, primarily rodents and dogs, also have significantly morphologically different upper respiratory system from humans. Despite these variables, the doses of smoke administered to these animals can be determined by examining tissue and blood samples. Dogs, which cannot be exposed to cigarette smoke via inhalation chambers as easily as can small rodents, require different methods of cigarette smoke exposure. These methods include thracheostomy, in which smoke is pumped through a tube directly into a hole cut in the dog's throat, or through a mask fitted to the dog's face.",
            "score": 105.85719299316406
        },
        {
            "docid": "40364158_18",
            "document": "Antibiotic use in livestock . The living conditions of animal feeding operations leads to a shotgun approach at targeting a sick population of livestock. Due to denser amounts of animals in smaller spaces, illness spreading and affecting a few animals can signal a precursor that more animals in an area will be infected by pathogens. In the United States, 80% of all antibiotics are given as feed additives. The antibiotics given to treat all the animals in dense area are not specific to each animal's illness and use a general approach to dosing. This leads to the antibiotics not being fully metabolized by the animals. This has been tested by levels of antibiotics still present in the manure of these animals.",
            "score": 105.83081817626953
        },
        {
            "docid": "443854_21",
            "document": "Rh disease . Animal studies had previously been conducted by William Pollack, using a rabbit model of Rh. This model, named the rabbit HgA-F system, was a perfect animal model of human Rh, and enabled Pollack's team to gain experience in preventing hemolytic disease in rabbits by giving specific HgA antibody, as was later done with Rh-negative mothers. One of the needs was a dosing experiment that could be used to determine the level of circulating Rh-positive cells in an Rh-negative pregnant female derived from her Rh-positive fetus. This was first done in the rabbit system, but subsequent human tests at the University of Manitoba conducted under Pollack's direction confirmed that this result matched the human dosing perfectly. The dose is 20 \u00b5G of antibody for 1mL of Rh-positive red cells.",
            "score": 104.90361785888672
        },
        {
            "docid": "8077127_23",
            "document": "Alternatives to animal testing . Toxicity testing typically involves studying adverse health outcomes in animals subjected to high doses of toxicants with subsequent extrapolation to expected human responses at lower doses. The system relies on the use of a 40+year-old patchwork of animal tests that are expensive (costing more than $3B per year), time-consuming, low-throughput and often provide results of limited predictive value for human health effects. The low-throughput of current toxicity testing approaches (which are largely the same for industrial chemicals, pesticides and drugs) has led to a backlog of more than 80,000 chemicals to which humans are potentially exposed whose potential toxicity remains largely unknown. In 2007, the National Research Council (NRC) released the report \"Toxicity Testing in the 21st Century: A Vision and a Strategy\", that charted a long-range strategic plan for transforming toxicity testing. The major components of the plan include the use of predictive, high-throughput cell-based assays (of human origin) to evaluate perturbations in key toxicity pathways, and to conduct targeted testing against those pathways. This approach will greatly accelerate our ability to test the vast \"storehouses\" of chemical compounds using a rational, risk-based approach to chemical prioritization, and provide test results that are hopefully far more predictive of human toxicity than current methods. Although a number of toxicity pathways have already been identified, most are only partially known and no common annotation exists. Mapping the entirety of these pathways (i.e. the Human Toxome ) will be a large-scale effort, perhaps on the order of the Human Genome Project.",
            "score": 104.71847534179688
        },
        {
            "docid": "2766_9",
            "document": "Ames test . One interesting result from the Ames test is that the dose response curve using varying concentrations of chemical is almost always linear, indicating that there is no threshold concentration for mutagenesis. It therefore suggests that, as with radiations, there may be no safe threshold for chemical mutagens or carcinogens. However some proposed that organisms can tolerate low level of mutagens due to protective mechanisms such as DNA repair, and threshold may exist for certain chemical mutagens. Bruce Ames himself argued against linear dose-response extrapolation from the high dose used in carcinogenesis tests in animal systems to the lower dose of chemicals normally encountered in human exposure, as the results may be false positives due to mitogenic response caused by the artificially high dose of chemicals used in such tests. He also cautioned against the \"hysteria over tiny traces of chemicals that may or may not cause cancer\", that \"completely drives out the major risks you should be aware of.\"",
            "score": 104.3749008178711
        },
        {
            "docid": "175596_49",
            "document": "Animal testing . There are several different types of acute toxicity tests. The (\"Lethal Dose 50%\") test is used to evaluate the toxicity of a substance by determining the dose required to kill 50% of the test animal population. This test was removed from OECD international guidelines in 2002, replaced by methods such as the fixed dose procedure, which use fewer animals and cause less suffering. Abbott writes that, as of 2005, \"the LD50 acute toxicity test ... still accounts for one-third of all animal [toxicity] tests worldwide\".",
            "score": 103.64608764648438
        },
        {
            "docid": "18641776_3",
            "document": "Human equivalent . Animal models are used to learn more about a disease, its diagnosis and its treatment, with animal models predicting human toxicity in up to 71% of cases. The human equivalent dose (HED) or human equivalent concentration (HEC) is the quantity of a chemical that, when administered to humans, produces an effect equal to that produced in test animals by a smaller dose. Calculating the HED is a step in carrying out a clinical trial of a pharmaceutical drug.",
            "score": 103.44367980957031
        },
        {
            "docid": "13519842_4",
            "document": "Dose-ranging study . The main goal of a dose-ranging study is to estimate the response vs. dose given, so as to analyze the efficacy and safety of the drug. Although such a response will nevertheless be available from phase III or phase IV trials, it is important to carry out dose-ranging studies in the earlier phase I or phase II stages. There are some advantages by using healthy volunteers. They are in a steady-state condition showing no different stages of disease and no variation due to disease. In addition, it is easy to recruit and select volunteers among varying age, sex, race etc. under identical conditions in which the test can be repeated.  The main reasons for this is to avoid trials in the later phases using doses that are significantly different from those that will subsequently be recommended for clinical use and also to avoid the need for modification of dosing schedules at later stages where a large amount of data has already been accumulated for a different dose range. The duration of action should be determined during dose-ranging study, as it will allow definition of the dosage schedule. Because it is hard to measure reliable pharmacodynamic parameter, it is difficult to determine the duration of action during early clinical trials. Other parameters instead are suggested as a tentative dosage, such as half-lives in plasma and urine in various test species and human, receptor binding in vitro, or pharmacodynamic data in vivo in animals.",
            "score": 103.03399658203125
        },
        {
            "docid": "39761773_6",
            "document": "Central nervous system effects from radiation exposure during spaceflight . Research with animal models that are irradiated with HZE nuclei has shown that important changes to the CNS occur with the dose levels that are of concern to NASA. However, the significance of these results on the morbidity to astronauts has not been elucidated. One model of late tissue effects suggests that significant effects will occur at lower doses, but with increased latency. It is to be noted that the studies that have been conducted to date have been carried out with relatively small numbers of animals (<10 per dose group); therefore, testing of dose threshold effects at lower doses (< 0.5 Gy) has not been carried out sufficiently at this time. As the problem of extrapolating space radiation effects in animals to humans will be a challenge for space radiation research, such research could become limited by the population size that is used in animal studies. Furthermore, the role of dose protraction has not been studied to date. An approach to extrapolate existing observations to possible cognitive changes, performance degradation, or late CNS effects in astronauts has not been discovered. New approaches in systems biology offer an exciting tool to tackle this challenge. Recently, eight gaps were identified for projecting CNS risks. Research on new approaches to risk assessment may be needed to provide the necessary data and knowledge to develop risk projection models of the CNS from space radiation.",
            "score": 102.76732635498047
        },
        {
            "docid": "1624750_14",
            "document": "Noscapine . Noscapine is currently being investigated as an antitumor agent in animal models of several human cancers. At very high doses it may cause polyploidy in animal cells by interfering with the spindles; at low doses - those relevant to medical use there seems to be a cut off and so it would be safe as used.",
            "score": 100.78533172607422
        },
        {
            "docid": "20359_27",
            "document": "Mutagen . Rodents are usually used in animal test. The chemicals under test are usually administered in the food and in the drinking water, but sometimes by dermal application, by gavage, or by inhalation, and carried out over the major part of the life span for rodents. In tests that check for carcinogens, maximum tolerated dosage is first determined, then a range of doses are given to around 50 animals throughout the notional lifespan of the animal of two years. After death the animals are examined for sign of tumours. Differences in metabolism between rat and human however means that human may not respond in exactly the same way to mutagen, and dosages that produce tumours on the animal test may also be unreasonably high for a human, i.e. the equivalent amount required to produce tumours in human may far exceed what a person might encounter in real life. Mice with recessive mutations for a visible phenotype may also be used to check for mutagens. Females with recessive mutation crossed with wild-type males would yield the same phenotype as the wild-type, and any observable change to the phenotype would indicate that a mutation induced by the mutagen has occurred. Mice may also be used for dominant lethal assays where early embryonic deaths are monitored. Male mice are treated with chemicals under test, mated with females, and the females are then sacrificed before parturition and early fetal deaths are counted in the uterine horns. Transgenic mouse assay using a mouse strain infected with a viral shuttle vector is another method for testing mutagens. Animals are first treated with suspected mutagen, the mouse DNA is then isolated and the phage segment recovered and used to infect \"E. coli\". Using similar method as the blue-white screen, the plaque formed with DNA containing mutation are white, while those without are blue.",
            "score": 100.3001708984375
        },
        {
            "docid": "37220_7",
            "document": "Infection . One way of proving that a given disease is \"infectious\", is to satisfy Koch's postulates (first proposed by Robert Koch), which demands that the infectious agent be identified only in patients and not in healthy controls, and that patients who contract the agent also develop the disease. These postulates were first used in the discovery that Mycobacteria species cause tuberculosis. Koch's postulates cannot be applied ethically for many human diseases because they require experimental infection of a healthy individual with a pathogen produced as a pure culture. Often, even clearly infectious diseases do not meet the infectious criteria. For example, \"Treponema pallidum\", the causative spirochete of syphilis, cannot be cultured \"in vitro\" \u2013 however the organism can be cultured in rabbit testes. It is less clear that a pure culture comes from an animal source serving as host than it is when derived from microbes derived from plate culture. Epidemiology is another important tool used to study disease in a population. For infectious diseases it helps to determine if a disease outbreak is sporadic (occasional occurrence), endemic (regular cases often occurring in a region), epidemic (an unusually high number of cases in a region), or pandemic (a global epidemic).",
            "score": 99.76750946044922
        },
        {
            "docid": "34382035_8",
            "document": "Phases of clinical research . Normally, a small group of 2\u2013100 healthy volunteers will be recruited. These trials are often conducted in a clinical trial clinic, where the subject can be observed by full-time staff. These clinical trial clinics are often run by contract research organization (CROs) who conduct these studies on behalf of pharmaceutical companies or other research investigators. The subject who receives the drug is usually observed until several half-lives of the drug have passed. This phase is designed to assess the safety (pharmacovigilance), tolerability, pharmacokinetics, and pharmacodynamics of a drug. Phase I trials normally include dose-ranging, also called dose escalation studies, so that the best and safest dose can be found and to discover the point at which a compound is too poisonous to administer. The tested range of doses will usually be a fraction of the dose that caused harm in animal testing. Phase I trials most often include healthy volunteers. However, there are some circumstances when clinical patients are used, such as patients who have terminal cancer or HIV and the treatment is likely to make healthy individuals ill. These studies are usually conducted in tightly controlled clinics called CPUs (Central Pharmacological Units), where participants receive 24-hour medical attention and oversight. In addition to the previously mentioned unhealthy individuals, \u201cpatients who have typically already tried and failed to improve on the existing standard therapies\" may also participate in phase I trials. Volunteers are paid a variable inconvenience fee for their time spent in the volunteer center.",
            "score": 99.27950286865234
        },
        {
            "docid": "33894099_28",
            "document": "Ticks of domestic animals . Vaccination against \"An. marginale\" is done using live strains of the cross-reactive \"An. centrale\". Vaccines are available on a commercial basis to immunize cattle against \"Babesia bovis\". This is made by serial infection of calves to attenuate the virulence of the strain of \"Babesia\", followed by splenectomy to produce many of the piroplasm stage in blood, which is then bottled for use. The vaccine is delivered containing the live protozoa to induce immunity without acute disease. \"Theileria annulata\" can be grown and attenuated in virulence by means of infecting cell cultures with the schizont stage of the protozoan. This is delivered as a frozen vaccine from which live parasites are thawed out before injection. Cattle can be protected against East Coast fever by an infection-and-treatment procedure. \"Rhipicephalus appendiculatus\" ticks are infected with \"Theileria parva\" under laboratory conditions; theilerial sporozoites are extracted from the ticks and stored in liquid nitrogen; infective doses of the live vaccine are delivered to identified cattle and a few days later a protective dose of antibiotic is delivered to stop the infection from developing into clinical East Coast fever. Vaccines are often highly effective, but the live parasite vaccines have problems of potential contamination with other microbes and induction of a carrier state which may be unwanted. Intensive attempts are made to develop vaccines to control these diseases using recombinant DNA techniques to synthesize the relevant antigens, but as with vaccines against human malaria this is a difficult technological challenge.",
            "score": 98.55064392089844
        },
        {
            "docid": "39761773_41",
            "document": "Central nervous system effects from radiation exposure during spaceflight . Reliable projections for CNS risks from space radiation exposure cannot be made at this time due to a paucity of data on the subject. Existing animal and cellular data do suggest that space radiation can produce neurological and behavioral effects; therefore, it is possible that mission operations will be impacted. The significance of these results on the morbidity to astronauts has not been elucidated, however. It is to be noted that studies, to date, have been carried out with relatively small numbers of animals (<10 per dose group); this means that testing of dose threshold effects at lower doses (<0.5 Gy) has not yet been carried out to a sufficient extent. As the problem of extrapolating space radiation effects in animals to humans will be a challenge for space radiation research, such research could become limited by the population size that is typically used in animal studies. Furthermore, the role of dose protraction has not been studied to date. An approach has not been discovered to extrapolate existing observations to possible cognitive changes, performance degradation, or late CNS effects in astronauts. Research on new approaches to risk assessment may be needed to provide the data and knowledge that will be necessary to develop risk projection models of the CNS from space radiation. A vigorous research program, which will be required to solve these problems, must rely on new approaches to risk assessment and countermeasure validation because of the absence of useful human radio-epidemiology data in this area.",
            "score": 98.46202087402344
        },
        {
            "docid": "8077127_3",
            "document": "Alternatives to animal testing . There is widespread agreement that a reduction in the number of animals used and the refinement of testing to reduce suffering should be important goals for the industries involved. Two major alternatives to \"in vivo\" animal testing are \"in vitro\" cell culture techniques and \"in silico\" computer simulation. However, some claim they are not true alternatives because simulations use data from prior animal experiments and cell cultures often require animal derived products, such as serum or cells. Others say that they cannot replace animals completely as they are unlikely to ever provide enough information about the complex interactions of living systems. Other alternatives include the use of humans for skin irritancy tests and donated human blood for pyrogenicity studies. Another alternative is so-called microdosing, in which the basic behaviour of drugs is assessed using human volunteers receiving doses well below those expected to produce whole-body effects. While microdosing produces important information about pharmacokinetics and pharmacodynamics it does not reveal information about toxicity or toxicology. Furthermore, it was noted by the Fund for the Replacement of Animals in Medical Experiments that despite the use of microdosing, \"animal studies will still be required\".",
            "score": 98.28718566894531
        },
        {
            "docid": "175596_76",
            "document": "Animal testing . Microdosing is another alternative to the use of animals in experimentation. Microdosing is a process whereby volunteers are administered a small dose of a test compound allowing researchers to investigate its pharmacological affects without harming the volunteers. Microdosing can replace the use of animals in pre-clinical drug screening and can reduce the number of animals used in safety and toxicity testing.",
            "score": 96.81298828125
        },
        {
            "docid": "46425_30",
            "document": "Substantia nigra . Soon after, MPTP was tested in animal models for its efficacy in inducing Parkinson's disease (with success). MPTP induced akinesia, rigidity, and tremor in primates, and its neurotoxicity was found to be very specific to the substantia nigra pars compacta. In other animals, such as rodents, the induction of Parkinson's by MPTP is incomplete or requires much higher and frequent doses than in primates. Today, MPTP remains the most favored method to induce Parkinson's disease in animal models.",
            "score": 96.3038330078125
        },
        {
            "docid": "4191_2",
            "document": "BCG vaccine . Bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). In countries where tuberculosis or leprosy is common, one dose is recommended in healthy babies as close to the time of birth as possible. In areas where tuberculosis is not common, only children at high risk are typically immunized, while suspected cases of tuberculosis are individually tested for and treated. Adults who do not have tuberculosis and have not been previously immunized but are frequently exposed may be immunized as well. BCG also has some effectiveness against Buruli ulcer infection and other nontuberculous mycobacteria infections. Additionally it is also often used as part of the treatment of bladder cancer. Rates of protection against tuberculosis infection vary widely and protection lasts up to twenty years. Among children it prevents about 20% from getting infected and among those who do get infected it protects half from developing disease. The vaccine is given by injection into the skin. Additional doses are not supported by evidence. It may also be used in the treatment of some types of bladder cancers. Serious side effects are rare. Often there is redness, swelling, and mild pain at the site of injection. A small ulcer may also form with some scarring after healing. Side effects are more common and potentially more severe in those with poor immune function. It is not safe for use during pregnancy. The vaccine was originally developed from \"Mycobacterium bovis\" which is commonly found in cows. While it has been weakened, it is still live. The BCG vaccine was first used medically in 1921. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Between 2011 and 2014 the wholesale price was $0.16 to $1.11 USD a dose in the developing world. In the United States it costs $100 to $200 USD. As of 2004 the vaccine is given to about 100 million children per year globally.",
            "score": 95.76773834228516
        },
        {
            "docid": "10176_6",
            "document": "Experimental cancer treatment . Clinical trials are the study of treatments in humans. The first-in-human tests of a potential treatment are called Phase I studies. Early clinical trials typically enroll a very small number of patients, and the purpose is to identify major safety issues and the \"maximum tolerated dose\", which is the highest dose that does not produce serious or fatal adverse effects. The dose given in these trials may be far too small to produce any useful effect. In most research, these early trials may involve healthy people, but cancer studies normally enroll only people with relatively severe forms of the disease in this stage of testing. On average, 95% of the participants in these early trials receive no benefit, but all are exposed to the risk of adverse effects. Most participants show signs of optimism bias (the irrational belief that they will beat the odds).",
            "score": 95.55085754394531
        },
        {
            "docid": "4402358_21",
            "document": "Theralizumab . The MHRA has further stated that the initial dose of TGN1412 was intended to be the first of a course of injections, with the dosage being ramped up over time. It has been reported that the initial dose was one five-hundredth of that which the animal studies indicated was a maximum safe dose. Dr. David Glover, an industry consultant, has suggested that because the antibody was raised against \"human\" CD28, the safe dosage may have been lower in humans than in animals. More concerningly, it has been shown that even using information available prior to the human first dose, it can be shown that the size of the initial dose was too high. Predictions showed that the 0.1\u00a0mg starting dose would bind to 86 to 91% of all CD28 receptors in the body, which means that even at the minimum starting dose selected, the investigators would anticipate seeing the maximum effect of the drug.",
            "score": 95.47525024414062
        },
        {
            "docid": "4584230_14",
            "document": "Biomarker (medicine) . Molecular biomarkers are often used in early drug development studies. For instance, they are used in phase I study for establishing doses and dosing regimen for future phase II studies. PD biomarkers are commonly observed to respond (either decrease or increase) proportionally with dose. This data, in conjunction with safety data, help determine doses for phase II studies.  In addition, Safety molecular biomarkers have been used for decades both in preclinical and clinical research. Since these tests have become mainstream tests, they have been fully automated for both animal and human testing. Among the most common safety tests are those of liver function (e.g., transaminases, bilirubin, alkaline phosphatase) and kidney function (e.g., serum creatinine, creatinine clearance, cystatin C). Others include markers of skeletal muscle(e.g., myoglobin) or cardiac muscle injury (e.g., CK-MB, troponin I or T), as well as bone biomarkers (e.g., bone-specific alkaline phosphatase).",
            "score": 94.97146606445312
        },
        {
            "docid": "575776_4",
            "document": "Lethal dose . The test was created by J.W. Trevan in 1927. The term \"semilethal dose\" is occasionally used with the same meaning, in particular in translations from non-English-language texts, but can also refer to a \"sub\"lethal dose; because of this ambiguity, it is usually avoided. LD is usually determined by tests on animals such as laboratory mice. In 2011 the US Food and Drug Administration approved alternative methods to LD for testing the cosmetic drug Botox without animal tests.",
            "score": 94.87616729736328
        },
        {
            "docid": "49110893_13",
            "document": "BIA 10-2474 . In terms of animal pharmacodynamics, the trial protocol reports that the biological activity of BIA 10-2474 was tested in models of predictive efficacy in treating pain. \u201cBIA 10-2474 produced analgesic/anti-inflammatory activity in the mouse Formalin-Paw and Tail-Flick tests in a time-and dose-dependent manner. BIA 10-2474 also markedly potentiated the antinociceptive effects of exogenous anandamide in the mouse Formalin-Paw and Tail-Flick tests\u201d. In other words, BIA 10-2474 worked as a pain-killer in mice using two different tests (the \u201canalgesic/anti-inflammatory\u201d effect); and, in mice that had been given a dose of the neurotransmitter anandamide, BIA 10-2474 also improved its effects in numbing pain (\u201cantinociceptive\u201d effect). The expert committee of the ANSM took the view that this was insufficient basis for commencing human trials, and that further evidence of BIA 10-2474 as an analgesic was warranted. The Committee's final report noted that in fact the original formalin paw study report presented additional data for the gabapentin comparator which was omitted in the Investigators Brochure. The final ANSM report stated that \"doses used in these tests differ greatly (from 0.3 to 10 mg/Kg), without it being possible to trace a dose\u2010effect curve or to estimate an effective dose 50 (which is a surprising shortcoming)\".",
            "score": 94.69081115722656
        },
        {
            "docid": "1672551_26",
            "document": "Concentrated animal feeding operation . Antibiotics are used heavily in CAFOs to both treat and prevent illness in individual animals as well as groups. The close quarters inside CAFOs promote the sharing of pathogens between animals and thus, the rapid spread of disease. Even if their stock are not sick, CAFOs will incorporate low doses of antibiotics into feed \u201cto reduce the chance for infection and to eliminate the need for animals to expend energy fighting off bacteria, with the assumption that saved energy will be translated into growth\u201d. This practice is an example of a non-therapeutic use of antibiotics. Such antibiotic use is thought to allow animals to grow faster and bigger, consequently maximizing production for that CAFO. Regardless, the World Health Organization has recommended that the non-therapeutic use of antibiotics in animal husbandry be reevaluated, as it contributes to the overuse of antibiotics and thus the emergence of resistant bacteria that can spread to humans. When bacteria naturally occurring in the animals\u2019 environment and/or body are exposed to antibiotics, natural selection results in bacteria, who have genetic variations that protect them from the drugs, to survive and spread their advantageously resistant traits to other bacteria present in the ecosystem. This is how the problem of antimicrobial resistance increases with the continued use of antibiotics by CAFOs. This is of concern to public health because resistant bacteria generated by CAFOs can be spread to the surrounding environment and communities via waste water discharge or aerosolization of particles.",
            "score": 94.65946197509766
        },
        {
            "docid": "18644_3",
            "document": "Median lethal dose . The test was created by J.W. Trevan in 1927. The term semilethal dose is occasionally used in the same sense, in particular with translations of foreign language text, but can also refer to a sublethal dose. LD is usually determined by tests on animals such as laboratory mice. In 2011, the U.S. Food and Drug Administration approved alternative methods to LD for testing the cosmetic drug Botox without animal tests.",
            "score": 93.47168731689453
        }
    ]
}